CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Cytomx Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.000 -- 00:00:03.900 Good afternoon, everyone. Thank you for standing by. 00:00:03.900 -- 00:00:09.440 Welcome to the Cytomics Therapeutics Second Quarter 2025 Financial Results Call. 00:00:09.440 -- 00:00:13.360 Please be advised that today's call is being recorded. 00:00:13.360 -- 00:00:18.700 I would now like to hand the conference over to your host for today, Chris Arjun, Cytomics 00:00:18.700 -- 00:00:22.980 Chief Financial Officer. Please go ahead. 00:00:24.080 -- 00:00:27.500 Thank you. Good afternoon, and thank you for joining us. 00:00:27.500 -- 00:00:31.920 Before we begin, I'd like to remind everyone that during this call, we will be making 00:00:31.920 -- 00:00:33.840 forward-looking statements. 00:00:33.840 -- 00:00:37.820 Because forward-looking statements relate to the future, they're subject to inherent 00:00:37.820 -- 00:00:42.940 uncertainties and risks that are difficult to predict, and many of which are 00:00:42.940 -- 00:00:47.980 outside of our control. Important risks and uncertainties are set forth in our 00:00:47.980 -- 00:00:52.660 most recent public filings with the SEC at sec.gov. 00:00:52.660 -- 00:00:57.740 We undertake no obligation to update any forward-looking statements, whether as a 00:00:57.740 -- 00:01:02.740 result of new information future developments or otherwise. 00:01:02.740 -- 00:01:06.980 Earlier this afternoon, we issued a press release that includes a summary of our second 00:01:06.980 -- 00:01:08.900 quarter 2025 00:01:08.900 -- 00:01:13.460 financial results and highlights recent progress at Cytomics. 00:01:13.460 -- 00:01:18.480 We encourage everyone to read today's press release and the associated materials which 00:01:18.480 -- 00:01:21.260 have been filed with the SEC. 00:01:21.260 -- 00:01:26.500 Ad...